Presentation Cardiovascular Interventions 2017 DAPT Duration After Stenting: An Updated Appraisal Presenter: Dean J. Kereiakes November 09, 2017
Presentation TCT 2017 SENIOR and Shorter DAPT Studies: Highlights Summary Presenter: Martin B. Leon, Marco Valgimigli, Olivier Varenne November 01, 2017
Presentation TCT 2017 Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié November 01, 2017
Presentation TCT 2017 What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants Presenter: Robert A. Harrington, Kurt Huber, Freek W.A. Verheugt November 01, 2017
Presentation TCT 2017 REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS Presenter: Robert A. Harrington, Gregg W. Stone, Harry Suryapranata November 01, 2017
Presentation TCT 2017 DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI Presenter: Robert A. Harrington, Gregg W. Stone, Elvin Kedhi November 01, 2017
Presentation TCT 2017 SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years Presenter: Robert A. Harrington, Gregg W. Stone, Olivier Varenne November 01, 2017
Presentation TCT 2017 What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis Presenter: Azeem Latib, Gregg W. Stone October 31, 2017
Presentation TCT 2017 FDA Perspectives on Short DAPT IDE Trials Presenter: Mitchell W. Krucoff, P.F. Adrian Magee October 31, 2017
Presentation TCT 2017 The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Ajay J. Kirtane October 31, 2017
Presentation TCT 2017 The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Marie-Claude Morice October 31, 2017
Presentation TCT 2017 TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry Presenter: Brij Maini, Petr Neuzil, Grzegorz Smolka, MD October 31, 2017
Presentation TCT 2017 Rationale and Studies of P2Y12 Inhibitor Monotherapy Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran October 30, 2017
Presentation TCT 2017 Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem October 30, 2017
Presentation TCT 2017 Switching to and From Cangrelor: When and How? Presenter: Dominick J. Angiolillo, Marco Valgimigli October 30, 2017
Presentation TCT 2017 Switching Between Oral P2Y12 Receptor Inhibitors: When and How? Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price October 30, 2017
Presentation TCT 2017 Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini October 30, 2017
Presentation TCT 2017 Impact of Race and Sex on Platelet Reactivity and Clinical Implications Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman October 30, 2017
Presentation TCT 2017 Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies! Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino October 30, 2017
Presentation TCT 2017 Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT Presenter: Ioannis Iakovou, Gert Richardt, Dean J. Kereiakes October 30, 2017